ECSP078030A - Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona - Google Patents

Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona

Info

Publication number
ECSP078030A
ECSP078030A EC2007008030A ECSP078030A ECSP078030A EC SP078030 A ECSP078030 A EC SP078030A EC 2007008030 A EC2007008030 A EC 2007008030A EC SP078030 A ECSP078030 A EC SP078030A EC SP078030 A ECSP078030 A EC SP078030A
Authority
EC
Ecuador
Prior art keywords
forms
methylpiperazin
quinolin
fluoro
amino
Prior art date
Application number
EC2007008030A
Other languages
English (en)
Inventor
Augustus Okhamafe
Joyce Chou
Rampurna Gullapalli
Eric Harwood
David Ryckman
Shuguang Zhu
Xiao Shang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37102961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP078030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP078030A publication Critical patent/ECSP078030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a las formas cristalinas no hidratadas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1H-bencimidazol-2-il]-1H-quinolin-2-ona, formulaciones farmacéuticas sólidas que contienen las mismas y métodos de uso. La presente invención además se refiere a los hidratos cristalinos de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1H-bencimidazol-2-il]-1H-quinolin-2-ona, formulaciones farmacéuticas que contienen los mismos y los métodos de uso relacionados con ellos. La presente invención también se refiere a los solvatos cristalinos de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1H-bencimidazol-2-il]-1H-quinolin-2-ona.
EC2007008030A 2005-05-23 2007-12-17 Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona ECSP078030A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68399905P 2005-05-23 2005-05-23

Publications (1)

Publication Number Publication Date
ECSP078030A true ECSP078030A (es) 2008-01-23

Family

ID=37102961

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007008030A ECSP078030A (es) 2005-05-23 2007-12-17 Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona

Country Status (20)

Country Link
US (2) US20110178097A1 (es)
EP (3) EP2270000B1 (es)
JP (2) JP2008542289A (es)
KR (1) KR101368519B1 (es)
CN (2) CN101218228A (es)
AU (1) AU2006249847B2 (es)
BR (1) BRPI0611375A2 (es)
CA (1) CA2609353C (es)
EC (1) ECSP078030A (es)
IL (2) IL187487A0 (es)
MA (1) MA29532B1 (es)
MX (1) MX2007014782A (es)
NO (1) NO20076635L (es)
NZ (1) NZ563692A (es)
PH (1) PH12013500773A1 (es)
RU (1) RU2425041C2 (es)
SG (1) SG154451A1 (es)
TN (1) TNSN07434A1 (es)
WO (1) WO2006127926A2 (es)
ZA (1) ZA200709903B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619370A2 (pt) * 2005-11-29 2011-09-27 Novartis Ag formulações de quinolinonas
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
PE20091628A1 (es) * 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
MX2010014566A (es) * 2008-07-03 2011-02-15 Novartis Ag Proceso de granulacion de fundido.
CN102822164A (zh) * 2010-03-26 2012-12-12 诺华有限公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的水合多晶形的制备
JP2013525292A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 有機化合物の組合せ
EP2558095B1 (en) 2010-04-16 2018-10-24 Novartis AG Organic compound for use in the treatment of liver cancer
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
US20130345234A1 (en) 2011-03-17 2013-12-26 Humphrey Athelstan Roy Gardner Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
BR112014005653A2 (pt) * 2011-09-15 2017-03-28 Novartis Ag uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140117457A (ko) 2012-01-31 2014-10-07 노파르티스 아게 Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
RU2015104537A (ru) 2012-07-11 2016-08-27 Новартис Аг Способы лечения стромальных опухолей желудочно-кишечного тракта
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
CN103804349A (zh) * 2012-11-01 2014-05-21 杨子娇 一类治疗青光眼的化合物及其用途
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CA2997697A1 (en) * 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Crystalline forms of grapiprant
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
CR20170104A (es) 2014-09-26 2017-05-31 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
TWI707851B (zh) * 2015-09-17 2020-10-21 日商大鵬藥品工業股份有限公司 哌嗪化合物的新穎結晶
CA3001969C (en) 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
BR112019027676A2 (pt) 2017-06-27 2020-09-15 Janssen Pharmaceutica Nv compostos de quinolinona
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
EA202190826A1 (ru) 2018-09-21 2021-06-16 Янссен Фармацевтика Нв Лечение холангиокарциномы
DE202019101126U1 (de) 2019-02-27 2019-03-06 Hgz Schutz Gmbh Wespenschutz
EP3946340A1 (en) 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN113645974A (zh) 2019-03-29 2021-11-12 詹森药业有限公司 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
AU2020265969B2 (en) 2019-04-30 2025-10-02 Beijing Tide Pharmaceutical Co., Ltd. Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
PH12022552093A1 (en) 2020-02-12 2023-11-29 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
US20230321087A1 (en) 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
US20250000858A1 (en) 2021-05-19 2025-01-02 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
CN120813357A (zh) 2023-02-13 2025-10-17 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
DE3248043A1 (de) 1982-12-24 1984-06-28 Bayer Ag, 5090 Leverkusen Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
WO1995018801A1 (en) 1994-01-08 1995-07-13 Rhone-Poulenc Agriculture Ltd. Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) * 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP2000506880A (ja) 1996-03-15 2000-06-06 ゼネカ・リミテッド シンノリン誘導体及びその使用
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
SE506547C2 (sv) 1996-06-20 1998-01-12 Asea Brown Boveri Förfarande och anordning för att detektera feltändning hos en förbränningsmotor
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
ATE222104T1 (de) 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
JP2002507598A (ja) 1998-03-26 2002-03-12 スージェン・インコーポレーテッド チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
NZ505921A (en) 1998-03-31 2003-08-29 Warner Lambert Co 1-[5-(2,6-Dimethylpiperidino)pentyl] substituted quinolone serine protease inhibitors and their use for treating thrombin related disorders
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF THE ACTIVITY OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1091945A1 (en) 1998-06-29 2001-04-18 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6174912B1 (en) * 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
GB9818310D0 (en) 1998-08-22 1998-10-14 Koninkl Philips Electronics Nv Thin film transistors and their manufacture
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
JP2003171280A (ja) 1999-06-07 2003-06-17 Fujisawa Pharmaceut Co Ltd 抗腫瘍効果増強剤
KR100298572B1 (ko) * 1999-08-19 2001-09-22 박찬구 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법
JP2003512353A (ja) * 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
KR100681724B1 (ko) * 1999-10-19 2007-02-28 머크 앤드 캄파니 인코포레이티드 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1351946A2 (en) * 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
JP4341949B2 (ja) * 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003026797A2 (en) 2001-09-21 2003-04-03 Solvias Ag Sealing system with flow channels
WO2003033472A1 (en) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
CA2501932C (en) * 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
US6774327B1 (en) 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
WO2005082340A2 (en) 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
US20060183750A1 (en) 2005-01-27 2006-08-17 Chiron Corporation Treatment of metastasized tumors
CN101146538A (zh) * 2005-01-27 2008-03-19 诺华疫苗和诊断公司 转移瘤的治疗
US20060261307A1 (en) * 2005-05-18 2006-11-23 Black D J Water Activated Organic Scavenger

Also Published As

Publication number Publication date
AU2006249847A1 (en) 2006-11-30
NO20076635L (no) 2008-02-25
JP2013224299A (ja) 2013-10-31
MA29532B1 (fr) 2008-06-02
NZ563692A (en) 2011-04-29
KR20080039845A (ko) 2008-05-07
RU2007147427A (ru) 2009-06-27
EP2270000B1 (en) 2015-07-29
CA2609353A1 (en) 2006-11-30
RU2425041C2 (ru) 2011-07-27
IL223350A0 (en) 2013-02-03
AU2006249847B2 (en) 2012-12-20
EP1904480A2 (en) 2008-04-02
CN101218228A (zh) 2008-07-09
PH12013500773A1 (en) 2014-11-10
EP2266974A1 (en) 2010-12-29
IL187487A0 (en) 2008-02-09
CA2609353C (en) 2015-04-28
BRPI0611375A2 (pt) 2010-08-31
TNSN07434A1 (en) 2009-03-17
CN102070614B (zh) 2014-01-15
US20120208825A1 (en) 2012-08-16
WO2006127926A2 (en) 2006-11-30
US8614216B2 (en) 2013-12-24
MX2007014782A (es) 2008-02-19
KR101368519B1 (ko) 2014-02-27
ZA200709903B (en) 2008-12-31
CN102070614A (zh) 2011-05-25
WO2006127926A3 (en) 2007-01-18
HK1152294A1 (en) 2012-02-24
SG154451A1 (en) 2009-08-28
US20110178097A1 (en) 2011-07-21
EP2270000A1 (en) 2011-01-05
JP2008542289A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
CO2022003782A2 (es) Inhibidores de kras g12d
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
NO20076635L (no) Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
ECSP088296A (es) Compuestos terapéuticos
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
AR052447A1 (es) Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
AR063561A1 (es) Dispositivos oculares y metodos para fabricar y utilizar los mismos
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
ECSP066750A (es) Derivados de indazol como inhibidores de lipasas sensibles a hormonas
UY30460A1 (es) Compuestos terapéuticos
ECSP088246A (es) Nuevos derivados de benzotiazolona
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
ATE464902T1 (de) Stabile pharmazeutische zubereitungen von montelukast-natrium
MX388981B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
MX2020007271A (es) Sales y cristales novedosos.
AR083268A1 (es) Conjugado de naloxol-peg cristalino
CR20120476A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
BRPI0507312A (pt) derivados de quinolina para uso como inibidores micobacterianos